Market Overview:
The global chemotherapy-induced nausea and vomiting drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing incidence of cancer, rising demand for effective antiemetic drugs, and growing number of clinical trials for new chemotherapeutic agents. However, patent expirations of key marketed products is expected to restrain the growth of this market during the forecast period. Based on type, the global chemotherapy-induced nausea and vomiting drugs market is segmented into existing drugs and pipeline drugs. The existing drug segment dominated the global market in 2017 owing to high demand for these products across regions. However, pipeline drugs are projected to witness higher CAGR during 2018–2030 due their potential benefits over existing therapies.
Product Definition:
Chemotherapy-induced nausea and vomiting (CINV) drugs are used to prevent or reduce the occurrence of nausea and vomiting associated with cancer chemotherapy. CINV drugs are important because they can help patients tolerate their chemotherapy treatment and improve their quality of life.
Existing Drugs:
Existing drugs, it's usage and growth factor in chemotherapy-induced nausea and vomiting market? To understand the current scenario of the global market for nausea and vomiting associated with cancer treatment, it is important to have a look at the drug development process.
The drug development process involves four stages: Phase I - Identification of an active ingredient (AI), dose, formulation, and method of administration that shows promise for treating a disease or condition.
Akynzeo (Netupitant-Palonosetron FDC):
AKYNNZEO (Netupitant-Palonosetron FDC) is a drug developed by Sun Pharmaceutical Industries Ltd. The generic name of the drug is palonosetron and its brand name is Netupitant. It’s a subtype 5 anti-vomit agent which works by increasing serotonin levels in the brain, thereby preventing vomiting center activation.
Application Insights:
The serotonin receptor antagonists segment dominated the global chemotherapy-induced nausea and vomiting drugs market in 2017. This is due to the high prevalence of cancer and increasing number of clinical trials for various products under this group. For instance, according to data published by NCBI, in 2019, around 23% of patients were diagnosed with cancer across the globe. Also, around 1 out of 5 people are estimated to be suffering from some form of gastrointestinal disease that requires medical attention.
Furthermore, growing R&D initiatives by key companies such as Pfizer Inc., Hoechst Marion Roussel ULC (Marion Merrell Dow), sanofi aventis; Astrazeneca LP; MedImmune LLC.; Novartis AG; and others will fuel product demand over the forecast period.
Regional Analysis:
North America dominated the global chemotherapy-induced nausea and vomiting market in 2017. This can be attributed to the presence of a large number of cancer patients, increasing adoption of immunotherapies, and rising preference for oral antiemetics over other available therapies. In addition, government initiatives promoting quality of life after diagnosis are likely to boost demand for these drugs in this region. For instance, Palliative Care Canada promotes awareness about palliative care services across Canada by conducting educational programs on behalf of healthcare professionals as well as the public at large.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to an increase in prevalence rates for cancer coupled with rise in government spending on healthcare research & development activities aimed at developing novel treatment options for emesis associated with chemotherapy administration.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the chemotherapy-induced nausea and vomiting drugs market. According to the American Cancer Society, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S., and approximately 600,920 people died from this disease. This number is expected to rise in future due to increase in aging population and unhealthy lifestyle habits such as smoking and alcohol consumption.
- Rising demand for effective antiemetic drugs: The chemotherapy-induced nausea and vomiting drugs market is growing due to rising demand for effective antiemetic drugs that can prevent or reduce these symptoms effectively. Chemotherapy-induced nausea and vomiting are among the most common side effects of chemotherapy treatment, which can significantly affect patients’ quality of life by causing severe discomfort and leading to a decreased appetite resulting in weight loss.
- Technological advancements: The development of novel drug delivery technologies has led to the introduction of new products with improved efficacy profiles into the chemotherapy-induced nausea and vomiting drugs market. These technologies include oral dissolving films (ODF), orally disintegrating tablets (ODT), transdermal patches, nasal sprays/inhalers etc., which offer patient convenience by eliminating or reducing swallowing difficulties associated with traditional solid dosage forms such as tablets or capsules..
Scope Of The Report
Report Attributes
Report Details
Report Title
Chemotherapy-Induced Nausea and Vomiting Drugs Market Research Report
By Type
Existing Drugs, Akynzeo (Netupitant-Palonosetron FDC), Aloxi (Palonosetron), Emend (Aprepitant), Kytril Generic (Granisetron), Zofran Generic (Ondansetron), Pipeline Drugs, SUSTOL (Granisetron Injection extended release), Rolapitant
By Application
Serotonin Receptor Antagonists, NK1 Receptor Antagonists
By Companies
Merck & Co., Inc., GlaxoSmithKline plc, Tesaro, Inc., Helsinn Group, F. Hoffmann-La Roche Ltd., Heron Therapeutics, Inc., Dr. Reddy's Laboratories Ltd., Acacia Pharma, Sun Pharmaceutical Industry Ltd., Otsuka Holdings Co., Ltd., Merck & Co., Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
215
Number of Tables & Figures
151
Customization Available
Yes, the report can be customized as per your need.
Global Chemotherapy-Induced Nausea and Vomiting Drugs Market Report Segments:
The global Chemotherapy-Induced Nausea and Vomiting Drugs market is segmented on the basis of:
Types
Existing Drugs, Akynzeo (Netupitant-Palonosetron FDC), Aloxi (Palonosetron), Emend (Aprepitant), Kytril Generic (Granisetron), Zofran Generic (Ondansetron), Pipeline Drugs, SUSTOL (Granisetron Injection extended release), Rolapitant
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Serotonin Receptor Antagonists, NK1 Receptor Antagonists
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Tesaro, Inc.
- Helsinn Group
- F. Hoffmann-La Roche Ltd.
- Heron Therapeutics, Inc.
- Dr. Reddy's Laboratories Ltd.
- Acacia Pharma
- Sun Pharmaceutical Industry Ltd.
- Otsuka Holdings Co., Ltd.
- Merck & Co., Inc.
Highlights of The Chemotherapy-Induced Nausea and Vomiting Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Existing Drugs
- Akynzeo (Netupitant-Palonosetron FDC)
- Aloxi (Palonosetron)
- Emend (Aprepitant)
- Kytril Generic (Granisetron)
- Zofran Generic (Ondansetron)
- Pipeline Drugs
- SUSTOL (Granisetron Injection extended release)
- Rolapitant
- By Application:
- Serotonin Receptor Antagonists
- NK1 Receptor Antagonists
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chemotherapy-Induced Nausea and Vomiting Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chemotherapy-induced nausea and vomiting (CINV) drugs are medications that can help to reduce the symptoms of CINV. These drugs work by blocking certain chemicals in the stomach that can cause nausea and vomiting.
Some of the major players in the chemotherapy-induced nausea and vomiting drugs market are Merck & Co., Inc., GlaxoSmithKline plc, Tesaro, Inc., Helsinn Group, F. Hoffmann-La Roche Ltd., Heron Therapeutics, Inc., Dr. Reddy's Laboratories Ltd., Acacia Pharma, Sun Pharmaceutical Industry Ltd., Otsuka Holdings Co., Ltd., Merck & Co., Inc..
The chemotherapy-induced nausea and vomiting drugs market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chemotherapy-Induced Nausea and Vomiting Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Chemotherapy-Induced Nausea and Vomiting Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Chemotherapy-Induced Nausea and Vomiting Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Chemotherapy-Induced Nausea and Vomiting Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Chemotherapy-Induced Nausea and Vomiting Drugs Market Size & Forecast, 2020-2028
4.5.1 Chemotherapy-Induced Nausea and Vomiting Drugs Market Size and Y-o-Y Growth
4.5.2 Chemotherapy-Induced Nausea and Vomiting Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Existing Drugs
5.2.2 Akynzeo (Netupitant-Palonosetron FDC)
5.2.3 Aloxi (Palonosetron)
5.2.4 Emend (Aprepitant)
5.2.5 Kytril Generic (Granisetron)
5.2.6 Zofran Generic (Ondansetron)
5.2.7 Pipeline Drugs
5.2.8 SUSTOL (Granisetron Injection extended release)
5.2.9 Rolapitant
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Serotonin Receptor Antagonists
6.2.2 NK1 Receptor Antagonists
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chemotherapy-Induced Nausea and Vomiting Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chemotherapy-Induced Nausea and Vomiting Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Existing Drugs
9.6.2 Akynzeo (Netupitant-Palonosetron FDC)
9.6.3 Aloxi (Palonosetron)
9.6.4 Emend (Aprepitant)
9.6.5 Kytril Generic (Granisetron)
9.6.6 Zofran Generic (Ondansetron)
9.6.7 Pipeline Drugs
9.6.8 SUSTOL (Granisetron Injection extended release)
9.6.9 Rolapitant
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Serotonin Receptor Antagonists
9.10.2 NK1 Receptor Antagonists
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Existing Drugs
10.6.2 Akynzeo (Netupitant-Palonosetron FDC)
10.6.3 Aloxi (Palonosetron)
10.6.4 Emend (Aprepitant)
10.6.5 Kytril Generic (Granisetron)
10.6.6 Zofran Generic (Ondansetron)
10.6.7 Pipeline Drugs
10.6.8 SUSTOL (Granisetron Injection extended release)
10.6.9 Rolapitant
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Serotonin Receptor Antagonists
10.10.2 NK1 Receptor Antagonists
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Existing Drugs
11.6.2 Akynzeo (Netupitant-Palonosetron FDC)
11.6.3 Aloxi (Palonosetron)
11.6.4 Emend (Aprepitant)
11.6.5 Kytril Generic (Granisetron)
11.6.6 Zofran Generic (Ondansetron)
11.6.7 Pipeline Drugs
11.6.8 SUSTOL (Granisetron Injection extended release)
11.6.9 Rolapitant
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Serotonin Receptor Antagonists
11.10.2 NK1 Receptor Antagonists
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Existing Drugs
12.6.2 Akynzeo (Netupitant-Palonosetron FDC)
12.6.3 Aloxi (Palonosetron)
12.6.4 Emend (Aprepitant)
12.6.5 Kytril Generic (Granisetron)
12.6.6 Zofran Generic (Ondansetron)
12.6.7 Pipeline Drugs
12.6.8 SUSTOL (Granisetron Injection extended release)
12.6.9 Rolapitant
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Serotonin Receptor Antagonists
12.10.2 NK1 Receptor Antagonists
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Existing Drugs
13.6.2 Akynzeo (Netupitant-Palonosetron FDC)
13.6.3 Aloxi (Palonosetron)
13.6.4 Emend (Aprepitant)
13.6.5 Kytril Generic (Granisetron)
13.6.6 Zofran Generic (Ondansetron)
13.6.7 Pipeline Drugs
13.6.8 SUSTOL (Granisetron Injection extended release)
13.6.9 Rolapitant
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Serotonin Receptor Antagonists
13.10.2 NK1 Receptor Antagonists
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chemotherapy-Induced Nausea and Vomiting Drugs Market: Competitive Dashboard
14.2 Global Chemotherapy-Induced Nausea and Vomiting Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck & Co., Inc.
14.3.2 GlaxoSmithKline plc
14.3.3 Tesaro, Inc.
14.3.4 Helsinn Group
14.3.5 F. Hoffmann-La Roche Ltd.
14.3.6 Heron Therapeutics, Inc.
14.3.7 Dr. Reddy's Laboratories Ltd.
14.3.8 Acacia Pharma
14.3.9 Sun Pharmaceutical Industry Ltd.
14.3.10 Otsuka Holdings Co., Ltd.
14.3.11 Merck & Co., Inc.
